- Home
- AACG vs CMMB Comparison
AACG vs CMMB Comparison
Compare AACG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- CMMB
- Stock Information
- Founded
- AACG 1999
- CMMB 2004
- Country
- AACG China
- CMMB Israel
- Employees
- AACG N/A
- CMMB N/A
- Industry
- AACG Other Consumer Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- CMMB Health Care
- Exchange
- AACG Nasdaq
- CMMB Nasdaq
- Market Cap
- AACG 24.4M
- CMMB 23.0M
- IPO Year
- AACG N/A
- CMMB N/A
- Fundamental
- Price
- AACG $0.89
- CMMB $1.16
- Analyst Decision
- AACG
- CMMB Strong Buy
- Analyst Count
- AACG 0
- CMMB 2
- Target Price
- AACG N/A
- CMMB $8.50
- AVG Volume (30 Days)
- AACG 11.9K
- CMMB 182.0K
- Earning Date
- AACG 08-06-2025
- CMMB 08-20-2025
- Dividend Yield
- AACG N/A
- CMMB N/A
- EPS Growth
- AACG N/A
- CMMB N/A
- EPS
- AACG N/A
- CMMB N/A
- Revenue
- AACG $37,997,003.00
- CMMB N/A
- Revenue This Year
- AACG N/A
- CMMB N/A
- Revenue Next Year
- AACG N/A
- CMMB N/A
- P/E Ratio
- AACG N/A
- CMMB N/A
- Revenue Growth
- AACG 21.24
- CMMB N/A
- 52 Week Low
- AACG $0.50
- CMMB $0.87
- 52 Week High
- AACG $1.10
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- AACG 54.01
- CMMB 38.60
- Support Level
- AACG $0.83
- CMMB $1.17
- Resistance Level
- AACG $0.80
- CMMB $1.20
- Average True Range (ATR)
- AACG 0.04
- CMMB 0.05
- MACD
- AACG 0.01
- CMMB 0.00
- Stochastic Oscillator
- AACG 69.25
- CMMB 16.46
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.